Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients
- Resource Type
- Article
- Authors
- Ma, Ning; Qiao, Hui; Tao, Hanchuan; Gan, Xinli; Shan, Zhili; Chen, Xiaomin; Zhou, Xiaojun
- Source
- Clinics and Research in Hepatology and Gastroenterology; 20220101, Issue: Preprints
- Subject
- Language
- ISSN
- 22107401
•The study investigates camrelizumab plus apatinib in metastatic gastric cancer (mGC).•ORR and DCR are 26.3% and 68.4% by camrelizumab plus apatinib treatment.•Median PFS of 7.0 (2.9-11.0) months and OS of 10.0 (7.4-12.6) months are realized.•Multiple metastases and ECOG PS link with prognosis to camrelizumab plus apatinib.•The adverse events are mostly mild to moderate and manageable.